DGAP-News: Press Release 4SC: Clinical data with 4SC's compound Vidofludimus in inflammatory bowel disease published in peer-reviewed scientific journal
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Miscellaneous
Press Release 4SC: Clinical data with 4SC's compound Vidofludimus in
inflammatory bowel disease published in peer-reviewed scientific
journal
02.11.2012 / 07:30
---------------------------------------------------------------------
Press Release
Clinical data with 4SC's compound Vidofludimus in inflammatory bowel
disease published in peer-reviewed scientific journal
Planegg-Martinsried/Germany, 2 November 2012 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, today announced, that
data from its clinical Phase II study with Vidofludimus in patients with
inflammatory bowel disease (IBD), which was completed and reported last
year, have been published online in a peer-reviewed article in Journal of
Crohns&Colitis (18 October 2012,
http://dx.doi.org/10.1016/j.crohns.2012.09.016, article in press, published
online ahead of print).
In the open-label, clinical Phase IIa study, vidofludimus had been
investigated in steroid-dependent patients with Crohn's disease and
Ulcerative colitis. The compound was safe and well tolerated and showed a
positive response rate in 88.5% of the patients by completely or partially
reducing patients' dependence on cortico-steroid drugs.
Dr. Ulrich Dauer, CEO of 4SC AG said: 'The publication of the convincing
clinical data in a peer-reviewed article in the Journal of Crohns&Colitis
emphasises the therapeutic potential of vidofludimus as a novel therapy of
autoimmune diseases, in particular in IBD. This also reinforces our
ambitions for our planned clinical Phase IIb study in Crohn's disease which
we intend to conduct preferably together with a partner.'
Ends
Details of the Publication:
Publication: Journal of Crohns and Colitis (J Crohns Colitis, 18 October
2012, http://dx.doi.org/10.1016/j.crohns.2012.09.016)
Title: 'Efficacy, safety and tolerability of vidofludimus in patients with
inflammatory bowel disease: The ENTRANCE study.'
Authors: K.R. Herrlinger a,o, M. Diculescu b, K. Fellermann c, H. Hartmann
d, S. Howaldt e, R. Nikolov f, A. Petrov g, W. Reindl h, J.M. Otte i, S.
Stoynov j, U. Strauch k, A. Sturm l, R. Voiosu m, A. Ammendola n, B.
Dietrich n, B. Hentsch n, E.F. Stange a
a Robert-Bosch-Hospital Stuttgart, Gastroenterology&Endocrinology,
Stuttgart, Germany
b Elias University Emergency Hospital Bucharest, Bucharest, Romania
c University Hospital Schleswig-Holstein, Campus Lübeck, Gastroenterology,
Lübeck, Germany
d Gastroenterologische Gemeinschaftspraxis, Herne, Germany
e Gastroenterologische Schwerpunktpraxis, Hamburg, Germany
f MHAT 'Sv. Ivan Rilski' Sofia, Clinic for Gastroenterology, Sofia,
Bulgaria
g MHAT Tokuda Hospital Sofia, Internal Disease Department, Sofia, Bulgaria
h Technical University Munich, Gastroenterology, Munich, Germany
i St. Josef-Hospital, University of Bochum, Bochum, Germany
j MHAT 'Tsaritsa Ioanna', Clinic for Gastroenterology Sofia, Sofia,
Bulgaria
k University Hospital Regensburg, Internal Medicine I, Regensburg, Germany
l CharitéBerlin, Hepatology&Gastroenterology, Berlin, Germany
m Colentina Clinical Hospital Bucharest, Gastroenterology, Bucharest,
Romania
n 4SC AG, Planegg-Martinsried, Germany
o Asklepios Hospital Heidberg, Internal Medicine I, Hamburg, Germany
About Vidofludimus
Vidofludimus is an orally administered small molecule for the treatment of
autoimmune disorders such as IBD (Crohn's disease and Ulcerative colitis).
The therapeutic efficacy of vidofludimus is based on an innovative dual
principle. Vidofludimus inhibits the expression of selected
pro-inflammatory cytokines, including interleukin-17 (IL-17A and IL-17F)
and interferon (IFN)-gamma that play crucial pathogenic roles in a variety
of autoimmune diseases. Vidofludimus also inhibits dihydroorotate
dehydrogenase (DHODH), a key enzyme of the pyrimidine biosynthesis, thereby
halting the proliferation of activated T and B cells which are involved in
the pathology of autoimmune disorders. Vidofludimus has completed several
Phase I and II trials showing a clean safety profile and encouraging
anti-inflammatory activity. Preclinical models demonstrate the broad
therapeutic potential of vidofludimus in autoimmune indications including
lupus, psoriasis, multiple sclerosis as well as transplant rejection.
About 4SC
The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various autoimmune and cancer indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC had 90 employees at
30 June 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt
Stock Exchange since December 2005.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com or contact:
4SC AG
Jochen Orlowski, Corporate Communications&Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
MC Services
Mareike Mohr, Raimund Gabriel
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 30
The Trout Group
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
End of Corporate News
---------------------------------------------------------------------
02.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
191070 02.11.2012
Themen in dieser Pressemitteilung:
press-release-4sc-clinical-data-with-4sc-s-compound-vidofludimus-in-inflammatory-bowel-disease-published-in-peer
reviewed-scientific-journal
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 198912
Anzahl Zeichen: 9417
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release 4SC: Clinical data with 4SC's compound Vidofludimus in inflammatory bowel disease published in peer-reviewed scientific journal"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
